Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 11Waldenstrom Macroglobulinemia 4Recurrence 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma 4Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Lymphoma, B-Cell 3Leukemia 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Burkitt Lymphoma 2Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Neoplasms, Plasma Cell 1Multi-centric Castleman's Disease 1Mastocytosis, Systemic 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Immunoblastic 1Leukemia, Mast-Cell 1Leukemia, Lymphoid 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Hypergammaglobulinemia 1Hematologic Neoplasms 1Hematologic Diseases 1

Interventions

ponatinib 2nilotinib 2Imatinib Mesylate 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2pembrolizumab 1ibrutinib 1Sertraline 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Biopsy 1BID protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Bone Marrow Diseases × ibrutinib × Clear all
NCT03514017 2026-03-02

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
5 enrolled 11 charts
LymphoidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡